APFED Donors Fund New Research | |||
| APFED's HOPE Pilot Grant was established to support researchers as they initiate new and innovative projects relevant to eosinophil-associated diseases that are likely to be impactful. Recipients of award are chosen through a competitive peer-review process. Learn more about the work that has been funded by APFED donors. HOPE Pilot Grant Amount: $100,000 over a 2-year period Project: Dr. Rosenblum will examine the cellular and molecular interaction of skin fibroblasts (cells that are part of the skin's structure) with eosinophils to determine the causes of disease and its relapse. Patient Impact: The findings of this research can lead to new therapies and can be applied to other eosinophil-associated diseases in the future. |  Michael Rosenblum, MD PhD Professor, Department of Dermatology, University of California, San Francisco | ||
| HOPE Pilot Grant Amount: $100,000 over a 2-year period Project: Dr. Kuang’s project entitled “Role of Human Eosinophils and T cells in EGID” will examine how blood eosinophils in EGIDs differ from those of other eosinophilic diseases, and how T cells in EGIDs differ from those in food allergy. Patient Impact: The information from this study will provide the foundation for developing new non-invasive diagnostic tools for EGIDs and other eosinophil-associated diseases. We are grateful for donors and community fundraisers that have supported the HOPE on the Horizon Research Grant Program. The advances toward a better understanding of eosinophil-associated diseases, non-invasive and accurate diagnostics, and therapeutic targets are not possible without the generosity of donations to our program. |  Fei Li Kuang, MD PhD Assistant Professor, Northwestern University Feinberg School of Medicine | ||
Clinical TrialsClinical trial participation is an individual, and important, decision. There are many advantages to participating in a trial, including care from medical teams experienced with the disease and the opportunity to try a new medication long before it is approved by the Food and Drug Administration to treat an indicated condition. If you choose to participate in a clinical trial, you have the right to understand fully what is expected of you, what the trial will involve and the potential risks to your health. You also have the right to withdraw your consent to participate at any time. For more resources about trial participation and informed consent, please see the resources available from the U.S. Department of Health and Human Services.Please note: Trials that are recruiting patients with eosinophil-associated disease and a search engine that can help match you to an enrolling trial appear below. Neither the list nor search engine results are considered exhaustive. The clinical trials listed here were verified as open and enrolling at the time the post was made, and are monitored periodically to ensure that the trial is still accepting participants. If a trial is no longer accepting patients, APFED may not be notified. If you find registration has closed for a trial that is still listed on this page, please notify mail@apfed.org. | Trials of Interest: | ||
Research Survey OpportunitiesQuestionnaires, surveys and patient interviews provide insights into the journey of someone living eosinophil-associated disease. Understanding patient experience helps guide improvements toward patient-centered care. Assessing the patient experience and the care they receive sheds light onto health care quality and unmet needs. |
OMEGA-A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular and Patient-Reported Outcomes in Pediatric and Adult Patients with Eosinophilic Esophagitis (EoE), Gastritis (EG), Gastroenteritis (EGE) and Colitis (EC)
